Celyad Oncology SA - American Depositary Shares (CYAD)
CYAD moved a median of 0.00% 30 minutes after news, and -0.61% by the close. How CYAD actually reacts to news — the realized, point-in-time move the market made, measured across 504 labeled events over its full measured history with zero look-ahead.
CYAD’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 26% | 389 |
| 30-min | 0.00% | 41% | 425 |
| 60-min | -0.04% | 36% | 441 |
| to close | -0.61% | 40% | 444 |
| Middle 50% of CYAD reactions | -1.01% to +0.45% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 504 |
Half of all Celyad Oncology SA - American Depositary Shares news events land between -1.01% and +0.45% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CYAD moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CYAD's baseline. Nothing else.
Recent CYAD events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Celyad Oncology Reports First Half Year 2026 Results | Press release | Business Wire | — | — | |
| Publication of a Transparency Notification Received from Tolefi SA (Article 14§1 of the Law of 2 May 2007) | Press release | Business Wire | — | — | |
| Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) | Press release | Business Wire | — | — | |
| Celyad Oncology Announces €500,000 Private Placement | Press release | Business Wire | — | — | |
| Celyad Oncology Reports Full Year 2025 Financial Results and Business Highlights | Press release | Business Wire | — | — | |
| Celyad Oncology Announces the Sale of C-CATHez ® Catheter | Press release | Business Wire | — | — | |
| Celyad Oncology: Publication of a Transparency Notification Received From Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007) | Press release | Business Wire | — | — | |
| Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) | Press release | Business Wire | — | — | |
| Celyad Oncology Announces Research Facility Divestiture | Press release | Business Wire | — | — | |
| Celyad Oncology Reports First Half Year 2025 Financial Results | Press release | Business Wire | — | — | |
| Celyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007) | Press release | Business Wire | — | — | |
| Celyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) | Press release | Business Wire | — | — | |
| Celyad Oncology Announces Discontinuation of R&D Activities | Press release | Business Wire | — | — | |
| Celyad Oncology SA: Publication of a Transparency Notification Received from Fortress Investment Group LLC | Press release | Business Wire | — | — | |
| Celyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) | Press release | Business Wire | — | — | |
| Celyad Oncology Announces €1 Million Private Placement | Press release | Business Wire | — | — | |
| Celyad Oncology Announces Strategic Review | Press release | Business Wire | — | — | |
| Celyad Oncology Reports Full Year 2024 Financial Results and Recent Business Highlights | Press release | Business Wire | — | — | |
| Celyad Oncology announces the publication of the preclinical and clinical data of CYAD-211 providing proof-of-concept of its miRNA-based shRNA platform | Press release | Business Wire | — | — | |
| Celyad Oncology to Present at the 2024 SITC Annual Meeting | Press release | Business Wire | — | — | |
| Celyad Oncology Announces Appointment of Matt Kane as Chief Executive Officer | Press release | Business Wire | — | — | |
| Celyad Oncology Reports First Half Year 2024 Financial Results and Recent Business Highlights | Press release | Business Wire | — | — | |
| Celyad Oncology Reports Full Year 2023 Financial Results and Recent Business Highlights | Press release | Business Wire | — | — | |
| Celyad Oncology Announces Intention to Terminate SEC Reporting Obligations | Press release | Business Wire | — | — | |
| Celyad Oncology Provides Fourth Quarter 2023 Business Update and 2024 Outlook | Press release | Business Wire | — | — | |
| Celyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLC | Press release | Business Wire | — | — | |
| Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) | Press release | Business Wire | — | — | |
| Celyad Announces Management Change | Press release | Business Wire | — | — | |
| Celyad Oncology SA: Publication of a transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007) | Press release | Business Wire | — | — | |
| Celyad Oncology SA: Publication of a transparency notification received from Fortress Investment Group LLC | Press release | Business Wire | — | — | |
| Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007) | Press release | Business Wire | — | — | |
| Celyad Oncology reports third quarter 2023 financial results and recent business highlights | Press release | Business Wire | — | — |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CYAD section they belong to.
Where else CYAD is measured.
CYAD earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| IMV Inc. - Common Shares (IMV) | 508 | -0.36% | 36% |
| CAMBREX (CBM) | 505 | 0.00% | 49% |
| DELMAR PHARMACEUTICALS (DMPI) | 504 | -0.13% | 38% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 504 | -0.09% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Celyad Oncology SA - American Depositary Shares's median reaction calculated?
Every labeled CYAD news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 504 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of CYAD's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CYAD's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.